Trials / Completed
CompletedNCT00722332
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Cangene Corporation · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the pharmacokinetics, safety and efficacy of HepaGam B in combination with antiviral therapy for the prevention of hepatitis B virus (HBV) recurrence following HBV-related orthotopic liver transplant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | HepaGam B | Hepatitis B Immunoglobulin |
Timeline
- Start date
- 2008-02-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2008-07-25
- Last updated
- 2013-11-01
Locations
16 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT00722332. Inclusion in this directory is not an endorsement.